"On behalf of everyone who could benefit from this treatment, we strongly urge the FDA to move swiftly in this next stage of its review," the group said. The news comes after the first Alzheimer's ...

The reform talks come in the wake of several contentious drug approval decisions, most notably the FDA’s 2021 clearance of Biogen and Eisai’s Alzheimer’s disease drug Aduhelm. Controversy around the ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

Here’s why older internet celebs — granfluencers — soon might be making rounds on the Alzheimer's drug marketing scene.

Authorization expands use of bezisterim in a Phase 2, placebo-controlled, multicenter trial assessing bezisterim’s impact on neurological ...

On-going Phase 2b clinical trial (ELPIS II) deemed pivotal and, if positive, acceptable for Biological License Application (BLA) submission for ...

Alzheimer’s disease doesn’t just impact those diagnosed, it touches families, caregivers, and entire communities.

The U.K. regulatory authority approved the Alzheimer's disease drug, Leqembi, last month. But the U.K. cost-effectiveness ...

Alzheimer’s disease (AD ... but a very few have been approved by the USFDA to intervene the disease’s pathogenesis. Past ...

Modeling suggests monthly maintenance dosing will keep biomarkers flat. Several talks showed how fluid biomarkers rebound after patients stop taking the drug. Likewise, cognitive decline returned to ...

A new study found that Alzheimer's medications called cholinesterase inhibitors may help slow down cognitive decline in ...

The treatment involves infusions of a new Alzheimer’s drug, lecanemab, which was approved by the Food and Drug Administration ...